Zembrace® SymTouch® is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: Use only if a clear diagnosis of migraine has been established. Not indicated for the preventive treatment of migraine.

Zembrace® SymTouch® is contraindicated in patients with a history of hemiplegic or basilar migraine. This is not the only contraindication for Zembrace® SymTouch®.

Please see complete Important Safety Information and full Prescribing Information.

Different treatment for different patients

When to prescribe

Zembrace® SymTouch®
for as little as $0*

The Access Pathways® Program is a best-in-class savings and support program. Access Pathways®, in partnership with BlinkRx, offers:

Eligible, commercially insured patients may pay as little as $0* per prescription, per month

Fast, free home delivery

Dedicated customer support to guide you and your patients through the process

Want more information?

Sign up today to learn more about Zembrace® SymTouch®.

    Note: This registration form is intended for healthcare providers only.

    *All fields required.

    Privacy Policy and Authorization

    By clicking the submit button below, you consent to the use by Upsher-Smith Laboratories, LLC and its third parties of the information you have provided to periodically send you information about Zembrace® SymTouch® or other products and promotions.

    Upsher-Smith Laboratories, LLC and its third parties use the information you provide for legitimate business purposes only and will not sell, share, or otherwise distribute your personal information to third parties. By joining, you acknowledge that your consent to receive automated messages is not required as a condition to purchase goods and services.


    1. Zembrace SymTouch [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: February 2021.
    2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276